Leveljump Health Stock Price, News & Analysis

LevelJump Healthcare Corp. (TSXV: JUMP) announces the Ontario Securities Commission has revoked the failure-to-file cease trade order (FFCTO) issued on May 7, 2024. The FFCTO was initially imposed due to the company's failure to file required annual financial statements and documentation for 2023.

Following a continuous disclosure review, LevelJump has:

• Refiled MD&A for year-end 2023
• Refiled interim financials for Q1 and Q2 2024
• Filed CEO/CFO certifications
• Refiled Annual Information Form
• Filed Q3 2024 financials

The company has committed to holding a shareholder meeting within three months of the FFCTO revocation. LevelJump's core business remains focused on providing telehealth solutions and in-person radiology services through its diagnostic centres. The company will now seek trading resumption approval from the TSX Venture Exchange.

LevelJump Healthcare reported its Q3 2024 financial results, showing significant improvement. Q3 revenues reached $4.45 million, up 57% year-over-year, with gross profit of $880,194. The quarterly net loss narrowed to $(18,960) from $(1,668,916) in 2023, while EBITDA was $704,834. For the first nine months of 2024, revenues totaled $12.9 million with EBITDA of $1,365,030. The company opened a new location at Yonge Sheppard in September and is currently working to resolve a Cease Trade Order with the OSC to reinstate trading on TSX Venture Exchange.

LevelJump Healthcare Corp. (TSXV: JUMP) has announced the opening of a new medical diagnostic imaging centre in Toronto, Ontario, through its subsidiary Canadian Teleradiology Services, Inc. (CTS). The Yonge Sheppard X-ray and Ultrasound (YSXU) clinic is located in North York and offers extended hours of operation. The 3,000 square foot facility features state-of-the-art equipment, including a new Samsung X-ray machine for faster scan times.

CEO Mitch Geisler emphasized the centre's role in reducing diagnostic imaging wait times in a densely populated area of Toronto. The company also plans to offer additional services through its upcoming Telehospital portal. Additionally, LevelJump has filed an application to revoke a failure to file cease trade order (FFCTO) issued by the Ontario Securities Commission on May 7, 2024, and intends to apply for reinstatement of trading on the TSX Venture Exchange once the FFCTO is revoked.

LevelJump Healthcare Corp (TSXV: JUMP) reported its Q2 2024 financial results, showing significant growth. Key highlights include:

- Canadian Teleradiology Services (CTS) revenues reached $4.4 million, a 42% year-over-year increase.

- Consolidated net income was $179,316 for Q2, with a year-to-date net loss of $(322,039).

- Q2 EBITDA was $655,484, with year-to-date EBITDA of $757,344.

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues, with expectations to grow to over $20 million as the Yonge Sheppard location opens. Gross margins are projected to reach 20% or more.

LevelJump Healthcare Corp. (TSXV: JUMP) has released its Q1 2024 financial results, highlighting strong revenue growth. Key points include:

- Canadian Teleradiology Services (CTS) revenues reached $4.1 million, a 46% year-over-year increase
- Consolidated net loss of $(501,480)
- Consolidated EBITDA of $97,742

CEO Mitch Geisler noted that the company is now tracking over $16 million annually in revenues. With the opening of the Yonge Sheppard location, LevelJump anticipates revenues to grow to over $20 million annually, with consistently positive EBITDA. The company uses non-IFRS financial measures like adjusted EBITDA to evaluate operating performance and liquidity.

LevelJump Healthcare Corp. (TSXV: JUMP) reported its 2023 financial results, highlighting a 36% year-over-year revenue increase to $12.6 million for its Canadian Teleradiology Services (CTS) subsidiary. The company's Q4 2023 revenues were $3.9 million, with a net loss of $(216,708). For the full year 2023, LevelJump reported a net loss of $(2,208,117), while CTS achieved a net profit of $1 million.

Key highlights include:

• Acquisition of 4 Independent Healthcare Facilities in Calgary, Alberta
• Q4 2023 EBITDA of $290,920 and Adjusted EBITDA of $340,920
• Full-year 2023 EBITDA of $(221,329) and Adjusted EBITDA of $78,671

LevelJump's management expects continued growth in 2024, focusing on completing its new Yonge Sheppard Center clinic and integrating the Alberta acquisition.